The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The Pharmaceutical Administration Bureau of the Macao Special Administrative Region (ISAF) has approved equecabtagene autoleucel (FUCASO) for the treatment of adult patients with
Nearly three years after treatment with the chimeric antigen receptor T-cell therapy ciltacabtagene autoleucel (cilta-cel), the risk of death was reduced by 45%
The incidence of hematologic malignancies presenting during pregnancy has increased, so Georgia Mills, MBBS (Hons), FRACP, FRCPA, of Northern Beaches Hospital in Sydney,
Orca-T is an allogeneic stem cell and T-cell immunotherapy that leverages high-purity regulatory T cells to prevent GVHD.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of pirtobrutinib for the
Octogenarians with B-cell lymphoma may be considered for chimeric antigen receptor (CAR) T-cell treatment, according to a study led by Mohamed A. Kharfan-Dabaja,
Individuals with tattoos, particularly larger ones, may have an increased risk of lymphoma and skin cancer, according to a recent study. “We are
A Viewpoints article published in The Lancet Haematology, calls for further research into the use of measurable residual disease (MRD) in hematologic malignancies.
The Brazilian Health Regulatory Agency (ANVISA) has approved ropeginterferon alfa-2b (BESREMi) for the treatment of adult patients with polycythemia vera (PV).
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to bexobrutideg (NX-5948), a first-in-class Bruton’s tyrosine kinase (BTK) degrader, for
